 |
|
|
 |
Events
Every year, there are numerous meetings, conferences, seminars and other events addressing chronic kidney disease. For more information, please visit the Renagel booth while attending these meetings.
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel. Patients should be informed to take Renagel with meals and to adhere to their prescribed diets. Please see accompanying full Prescribing Information. | |
|
|
|
Genzyme Corporate
